Form 4: Astronics CEO Gundermann Granted New Stock Options
Insider Transaction Report
Astronics Corp. CEO Peter J. Gundermann was granted 29,750 stock options with an exercise price of $51.72, effective December 4, 2025, under a pre-arranged plan.
Summary
- Peter J. Gundermann, President/CEO and Director of Astronics Corp. (ATRO), reported changes in beneficial ownership via a Form 4 filing.
- On December 4, 2025, Gundermann acquired 29,750 stock options to purchase $.01 par value Common Stock.
- These newly granted options have an exercise price of $51.72 per share, become exercisable on December 4, 2026, and expire on December 4, 2035.
- The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan for equity securities.
- Gundermann's beneficial ownership also includes 83,906.608 shares of Common Stock and 747,911 shares of Class B Stock.
- He also holds various other outstanding stock options with exercise prices ranging from $9.74 to $35.61 and expiration dates up to 2034.
- Additionally, Gundermann holds Restricted Stock Units (RSUs) with target amounts of 9,206, 26,450, and 25,250 units, whose vesting is contingent on Astronics Corp.'s average annual adjusted EBITDA performance for periods ending December 31, 2025, 2026, and 2027, respectively.
Sentiment
Score: 7
Explanation: The filing reports a routine executive equity grant under a pre-arranged plan, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. The performance-based RSUs further reinforce this alignment, indicating a focus on future company performance.
Positives
- The grant of new stock options to the CEO aligns management's long-term interests with shareholder value creation.
- The use of a Rule 10b5-1(c) plan for the transaction indicates a pre-arranged plan, which can reduce concerns about opportunistic insider trading.
- Performance-based Restricted Stock Units incentivize the CEO to achieve specific financial targets (adjusted EBITDA) for the company.
Risks
- The vesting of a significant portion of the CEO's Restricted Stock Units (RSUs) is contingent on Astronics Corp.'s average annual adjusted EBITDA performance for specific future periods (2023-2025, 2024-2026, and 2025-2027), introducing performance risk for the executive's compensation.
- The value of stock options is subject to market fluctuations and the company's stock performance, meaning the options may not become 'in the money' if the stock price does not exceed the exercise price.
Future Outlook
The vesting of a significant portion of the CEO's Restricted Stock Units (RSUs) is tied to Astronics Corp.'s average annual adjusted EBITDA performance for the periods spanning 2023-2025, 2024-2026, and 2025-2027. This indicates a forward-looking compensation structure designed to incentivize future financial performance. The new options granted also have a long-term expiration date (2035), suggesting a long-term view on value creation and management's belief in the company's future growth potential.
Industry Context
This Form 4 filing details an executive equity grant, which is a standard component of compensation packages across various industries. It does not provide specific insights into broader industry trends or competitive dynamics, but rather focuses on internal corporate governance and executive incentive alignment.
Related Party Transactions
- The filing details an equity grant to Peter J. Gundermann, the President/CEO and a Director of Astronics Corp., which is a transaction between the company and a related party (an executive officer and director).
Stakeholder Impact
- Shareholders: The grant of performance-based equity to the CEO aims to align his interests with long-term shareholder value creation, potentially benefiting shareholders if performance targets are met.
- Employees: The compensation structure for the CEO may set a precedent or reflect the company's overall approach to executive incentives, potentially influencing employee morale and retention.
Next Steps
- The newly granted options will become exercisable on December 4, 2026.
- The 2023-2025 performance-based RSUs are scheduled to vest on February 23, 2026, contingent on actual adjusted EBITDA performance.
- The 2024-2026 performance-based RSUs are scheduled to vest on February 23, 2027, contingent on actual adjusted EBITDA performance.
- The 2025-2027 performance-based RSUs are scheduled to vest on February 27, 2028, contingent on actual adjusted EBITDA performance.
Key Dates
| Date | Description |
|---|---|
| 12/14/2017 | Date exercisable for 14,460 options (Com Stk) and 2,169 options (CL B STK) with $31.76 exercise price. |
| 12/12/2018 | Date exercisable for 26,300 options (Com Stk) and 3,945 options (CL B STK) with $35.61 exercise price. |
| 12/13/2019 | Date exercisable for 34,790 options (Com Stk) with $31.57 exercise price. |
| 12/09/2020 | Date exercisable for 61,200 options (Com Stk) with $30.04 exercise price. |
| 01/22/2022 | Date exercisable for 98,900 options (Com Stk) with $14.45 exercise price. |
| 12/09/2022 | Date exercisable for 115,800 options (Com Stk) with $11.13 exercise price. |
| 01/01/2023 | Start of performance period for 9,206 target Restricted Stock Units (RSUs) vesting on Feb 23, 2026. |
| 12/16/2023 | Date exercisable for 125,000 options (Com Stk) with $9.74 exercise price. |
| 01/01/2024 | Start of performance period for 26,450 target Restricted Stock Units (RSUs) vesting on Feb 23, 2027. |
| 12/07/2024 | Date exercisable for 83,900 options (Com Stk) with $15.15 exercise price. |
| 01/01/2025 | Start of performance period for 25,250 target Restricted Stock Units (RSUs) vesting on Feb 27, 2028. |
| 12/04/2025 | Transaction date for the acquisition of 29,750 new stock options with an exercise price of $51.72. |
| 12/05/2025 | Date exercisable for 75,800 options (Com Stk) with $16.55 exercise price. |
| 12/08/2025 | Filing date of the Form 4. |
| 12/31/2025 | End of performance period for 9,206 target Restricted Stock Units (RSUs) vesting on Feb 23, 2026. |
| 02/23/2026 | Vesting date for 9,206 target Restricted Stock Units (RSUs) based on 2023-2025 adjusted EBITDA performance. |
| 12/04/2026 | Date exercisable for the 29,750 new stock options granted on 12/04/2025. |
| 12/14/2026 | Expiration date for 14,460 options (Com Stk) and 2,169 options (CL B STK) with $31.76 exercise price. |
| 12/31/2026 | End of performance period for 26,450 target Restricted Stock Units (RSUs) vesting on Feb 23, 2027. |
| 02/23/2027 | Vesting date for 26,450 target Restricted Stock Units (RSUs) based on 2024-2026 adjusted EBITDA performance. |
| 12/12/2027 | Expiration date for 26,300 options (Com Stk) and 3,945 options (CL B STK) with $35.61 exercise price. |
| 12/31/2027 | End of performance period for 25,250 target Restricted Stock Units (RSUs) vesting on Feb 27, 2028. |
| 02/27/2028 | Vesting date for 25,250 target Restricted Stock Units (RSUs) based on 2025-2027 adjusted EBITDA performance. |
| 12/13/2028 | Expiration date for 34,790 options (Com Stk) with $31.57 exercise price. |
| 12/09/2029 | Expiration date for 61,200 options (Com Stk) with $30.04 exercise price. |
| 01/22/2031 | Expiration date for 98,900 options (Com Stk) with $14.45 exercise price. |
| 12/09/2031 | Expiration date for 115,800 options (Com Stk) with $11.13 exercise price. |
| 12/16/2032 | Expiration date for 125,000 options (Com Stk) with $9.74 exercise price. |
| 12/07/2033 | Expiration date for 83,900 options (Com Stk) with $15.15 exercise price. |
| 12/05/2034 | Expiration date for 75,800 options (Com Stk) with $16.55 exercise price. |
| 12/04/2035 | Expiration date for the 29,750 new stock options granted on 12/04/2025. |
Recommendation
holdThis Form 4 filing reports a standard equity grant to the CEO under a Rule 10b5-1 plan. Such grants are typical components of executive compensation designed to align management incentives with long-term shareholder value. It does not provide new information that would fundamentally alter the investment thesis for Astronics Corp., hence a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.
Keywords
Astronics Corp, ATRO, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, CEO Compensation, Peter J. Gundermann, Equity Grant, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.